EB-2 NIWLife sciences and medicineIndividualDecided 2018Sustained
Outcome: Sustained
AUG222018_01B5203
Merit and national importanceMetWell positionedMetBalance favors a waiverMet
Our summary
A public health researcher with focus on cancer drug safety sought NIW under EB-2. AAO found all three Dhanasar prongs met: proposed research on checkpoint inhibitor adverse effects has substantial merit and national importance; petitioner is well positioned based on past experience; waiver favors U.S. on balance. Appeal sustained.
Official PDF
Official PDF ↗Published by USCIS. The summary is ours, in our own words; the decision text is on uscis.gov.
What the AAO accepted
- Merit and national importance · Research on adverse effects of cancer immunotherapy has substantial merit and national importance to drug safety
- Well positioned · Past research experience in cancer epidemiology and adverse effect studies demonstrates ability to advance proposed work
- Balance favors a waiver · Track record of successful research and significance of proposed work benefit U.S. healthcare interests
What was missing
Every criterion in the table was found met.
Criteria
| Criterion | Reading | Why |
|---|---|---|
 Merit and national importance | Met | Research on adverse effects of cancer immunotherapy has substantial merit and national importance to drug safety |
 Well positioned | Met | Past research experience in cancer epidemiology and adverse effect studies demonstrates ability to advance proposed work |
 Balance favors a waiver | Met | Track record of successful research and significance of proposed work benefit U.S. healthcare interests |
A published decision describes one case. It is not legal advice and not a prediction for yours.